06660 艾美疫苗
按盘价 
3.270 -0.040 (-1.208%) 盈利能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 资产回报率 (%) | -3.804% | -16.124% | -3.772% | -10.858% | 9.931% |
| 股东资金回报率 (%) | -7.912% | -30.245% | -6.487% | -16.665% | 15.291% |
| 资本运用回报率 (%) | -6.563% | -27.918% | -4.823% | -10.654% | 10.663% |
边际利润分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 毛利率 (%) | 74.201% | 75.877% | 81.297% | 82.458% | 82.669% |
| 未计利息、税项、折旧及摊销前利润率 (%) | -5.088% | -173.716% | -19.993% | -29.455% | 37.805% |
| 税前边际利润率 (%) | -22.623% | -191.217% | -34.347% | -38.640% | 29.664% |
| 纯利率 (%) | -21.574% | -109.561% | -25.283% | -44.122% | 23.156% |
变现能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 流动比率 (X) | 0.773 X | 0.954 X | 1.133 X | 1.502 X | 2.156 X |
| 速动比率 (X) | 0.623 X | 0.758 X | 0.909 X | 1.268 X | 1.933 X |
财务杠杆分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 总负债 / 总资产比率 (%) | 50.630% | 46.439% | 33.967% | 29.397% | 27.012% |
| 总债项 / 总资产比率 (%) | 25.174% | 24.726% | 15.758% | 8.058% | 5.014% |
| 净债项 / 总资产比率 (%) | 18.416% | 16.696% | 8.602% | 0.046% | -18.511% |
| 总债项 / 股东资金比率 (%) | 54.710% | 49.293% | 28.198% | 13.294% | 6.869% |
| 长期债项 / 股东资金比率 (%) | 12.881% | 15.630% | 7.432% | 4.623% | 1.364% |
| 净债项 / 股东资金比率 (%) | 40.024% | 33.284% | 15.392% | 0.075% | -25.362% |
| 净现金 / (债项) ($) | (13.47亿) | (12.12亿) | (7.63亿) | (3.69百万) | 8.68亿 |
| 每股净现金 / (债项) ($) | (1.112) | (1.001) | (0.630) | -- | -- |
| 总债项 / 资本运用比率 (%) | 43.590% | 38.532% | 21.109% | 10.003% | 6.608% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | 31.868 X |
营运效率分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 存货周转率日数 (日) | 535.335日 | 646.405日 | 673.245日 | 410.887日 | 309.562日 |
| 应收贸易帐周转率日数 (日) | 302.335日 | 316.239日 | 305.532日 | 224.737日 | 146.482日 |
| 应付贸易帐周转率日数 (日) | 15.800日 | 20.585日 | 18.097日 | 10.430日 | 9.013日 |
| 备注： | 实时报价更新时间为16/05/2025 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB -277,234 |
| 增长率 | -78.691% |
| 每股盈利/(亏损) | RMB -0.230 |
| 每股账面资产净值 (¥) | RMB 2.779 |